

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ImaRx Pharmaceutical Corporation	05/17/2006

RECEIVING PARTY DATA

Name:	ImaRx Therapeutics, Inc.
Street Address:	1635 E. 18th Street
City:	Tucson
State/Country:	ARIZONA
Postal Code:	85719

PROPERTY NUMBERS Total: 68

Property Type	Number
Patent Number:	5368840
Patent Number:	5420176
Patent Number:	5458127
Patent Number:	5466438
Patent Number:	5469854
Patent Number:	5517993
Patent Number:	5525326
Patent Number:	5527521
Patent Number:	5542935
Patent Number:	5547656
Patent Number:	5558092
Patent Number:	5571497
Patent Number:	5580575
Patent Number:	5585112
Patent Number:	5624662

PATENT

500105294

REEL: 017626 FRAME: 0618

CH \$2720.00 5368840

Patent Number:	5628327
Patent Number:	5639442
Patent Number:	5645816
Patent Number:	5656211
Patent Number:	5658550
Patent Number:	5681542
Patent Number:	5705187
Patent Number:	5714528
Patent Number:	5714529
Patent Number:	5715824
Patent Number:	5733572
Patent Number:	5736121
Patent Number:	5762910
Patent Number:	5770222
Patent Number:	5773024
Patent Number:	5776429
Patent Number:	5824312
Patent Number:	5830430
Patent Number:	5846517
Patent Number:	5853752
Patent Number:	5874062
Patent Number:	5885549
Patent Number:	5922304
Patent Number:	5935553
Patent Number:	5948387
Patent Number:	5976500
Patent Number:	5977538
Patent Number:	5985244
Patent Number:	5985246
Patent Number:	5997898
Patent Number:	6001335
Patent Number:	6010682
Patent Number:	6013035
Patent Number:	6024939
Patent Number:	6028066

Patent Number:	6030348
Patent Number:	6033646
Patent Number:	6039557
Patent Number:	6056938
Patent Number:	6071494
Patent Number:	6071495
Patent Number:	6088613
Patent Number:	6090800
Patent Number:	6117414
Patent Number:	6120751
Patent Number:	6123923
Patent Number:	6139819
Patent Number:	6143276
Patent Number:	6146657
Patent Number:	6231834
Patent Number:	6443898
Patent Number:	6638767
Patent Number:	6743779

CORRESPONDENCE DATA

Fax Number: (858)677-1465
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: (858) 638-6756
 Email: aldon.griffis@dlapiper.com
 Correspondent Name: Lisa A. Haile, J.D., Ph.D.
 Address Line 1: 4365 Executive Drive, Suite 1100
 Address Line 2: DLA Piper Rudnick Gray Cary US LLP
 Address Line 4: San Diego, CALIFORNIA 92121-2133

ATTORNEY DOCKET NUMBER:	IMARX1000
NAME OF SUBMITTER:	Lisa A. Haile, J.D., Ph.D.

Total Attachments: 4
 source=IMARX1000 Patent Assignments (ImaRx Pharmaceutical Corporation to ImaRx Therapeutics, Inc.)#page1.tif
 source=IMARX1000 Patent Assignments (ImaRx Pharmaceutical Corporation to ImaRx Therapeutics, Inc.)#page2.tif
 source=IMARX1000 Patent Assignments (ImaRx Pharmaceutical Corporation to ImaRx Therapeutics, Inc.)#page3.tif
 source=IMARX1000 Patent Assignments (ImaRx Pharmaceutical Corporation to ImaRx Therapeutics, Inc.)#page4.tif

ASSIGNMENT

This assignment ("Assignment") is made by ImaRx Pharmaceutical Corporation of Tucson, Arizona (collectively, the "Assignor") to Assignee, **ImaRx Therapeutics, Inc.** ("Assignee"), having a place of business at 1635 E. 18th Street, Tucson, Arizona 85719.

Recitals

A. The Assignor has invented new and useful inventions as identified on the attached Schedule 1 for which a patent was issued in the United States Patent and Trademark Office.

B. The parties desire to have a recordable instrument assigning from the Assignor to the Assignee the entire rights, title and interest in and to the invention, the application and all Letters Patent in the United States and throughout the world that may be granted or issued for the invention or that derive a right of priority from the application (including, without limitation, all divisional, continuation, continuation-in-part and continued prosecution applications thereof, and all reissues and reexaminations thereof, and all foreign counterparts thereof) (collectively, the "Invention Patents").

Agreement

NOW, THEREFORE, in accordance with the obligations to assign the Invention Patents and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor agrees to the foregoing and as follows:

1. The Assignor does and will sell, assign and transfer to Assignee, such Assignor's entire rights, title, and interest in and to each of the Invention Patents, including, without limitation, the rights to file foreign applications directly in the name of the Assignee and

to claim for any such foreign applications any priority rights to which such applications are entitled under international conventions, treaties, or otherwise.

2. The Assignor agrees that, upon request and without further compensation, but at no expense to such Assignor, such Assignor and such Assignor's legal representatives and assigns will do all lawful acts, including the execution of papers and the giving of testimony, that may be necessary or desirable for obtaining, sustaining, reissuing, or enforcing each of the Invention Patents in the United States and throughout the world, and for perfecting, recording, or maintaining the title of Assignee, and Assignee's successors and assigns, in and to each of the Invention Patents in the United States and throughout the world. In the event that Assignee is unable for any reason to secure the Assignor's signatures to any document that may be necessary or desirable for obtaining, sustaining, reissuing, or enforcing each of the Invention Patents in the United States and throughout the world, or for perfecting, recording, or maintaining the title of Assignee, and Assignee's successors and assigns, in and to each of the Invention Patents in the United States and throughout the world, the Assignor hereby irrevocably designates and appoints Assignee and Assignee's duly authorized officers and agents as such Assignor's agents and attorneys-in-fact to act for and on such Assignor's behalf and instead of such Assignor to execute such document, all with the same legal force and effect as if executed by such Assignor.

3. The Assignor represents and warrants that such Assignor has not granted and will not grant to others either (1) any rights, title or interest in and to any of the Invention Patents, or (2) any rights inconsistent with the rights granted herein.


4. The Assignor authorizes and requests the Assistant Commissioner for Patents of the United States and the various counterparts thereof throughout the world to issue and/or grant any Letters Patent granted for each of the Invention Patents to Assignee, its successors and assigns, as the assignee of the entire interest in such Invention Patents.

5. This Assignment constitutes the entire agreement with respect to its subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. No waiver, amendment, or modification of this Assignment shall be effective against the Assignee, unless in writing executed by a duly authorized representative of the Assignee. This Assignment shall be governed in all respects by the laws of the United States of America and by the laws of the state/province of California, as such laws are applied to agreements entered into and to be performed entirely within California between California residents. Each of the parties irrevocably consents to the exclusive personal jurisdiction of the federal and state courts located in California, as applicable, for any matter arising out of or relating to this Assignment, except that in any action seeking to enforce any order or any judgment of such federal or state courts located in California, such personal jurisdiction shall be nonexclusive. A breach of any of the promises or agreements contained herein will result in irreparable and continuing damage to Assignee for which there will be no adequate remedy at law, and Assignee shall be entitled to injunctive relief and/or a decree of specific performance, and such other relief as may be proper.

IN WITNESS WHEREOF, the Assignor has executed this Assignment on the date(s) provided below.

Assignor : ImaRx Pharmaceutical Corporation

Date: 5/17/06

Signature: 
Evan C. Unger
President and CEO
ImaRx Pharmaceutical Corporation

SCHEDULE 1
PATENT NUMBERS

5,368,840	5,420,176	5,458,127
5,466,438	5,469,854	5,517,993
5,525,326	5,527,521	5,542,935
5,547,656	5,558,092	5,571,497
5,580,575	5,585,112	5,624,662
5,628,327	5,639,442	5,645,816
5,656,211	5,658,550	5,681,542
5,705,187	5,714,528	5,714,529
5,715,824	5,733,572	5,736,121
5,762,910	5,770,222	5,773,024
5,776,429	5,824,312	5,830,430
5,846,517	5,853,752	5,874,062
5,885,549	5,922,304	5,935,553
5,948,387	5,976,500	5,977,538
5,985,244	5,985,246	5,997,898
6,001,335	6,010,682	6,013,035
6,024,939	6,028,066	6,030,348
6,033,646	6,039,557	6,056,938
6,071,494	6,071,495	6,088,613
6,090,800	6,117,414	6,120,751
6,123,923	6,139,819	6,143,276
6,146,657	6,231,834	6,443,898
6,638,767	6,743,779	